This article suggests using biomarkers alongside oxygen measurements to better prescribe home oxygen therapy in COPD patients, highlighting potential benefits.
Long-term oxygen therapy (LTOT), that is, home oxygen prescribed for at least 15–18 hours per day, improves survival in patients with COPD and severe hypoxemia. LTOT does not benefit all severely hypoxemic patients, however, a large proportion of patients who receive home oxygen do not benefit from therapy, whereas a number of patients who would benefit from home oxygen are denied therapy because they do not meet the current prescription criteria that are accepted worldwide. To overcome this problem, we suggest that the practice of LTOT prescription be individualized. Biomarkers of cellular or vascular dysfunction should complement the mere measurement of P aO 2 or S p O 2 to decide who should receive LTOT. In this article, we present clinical vignettes to illustrate the application of this proposal and describe a protocol for a clinical trial designed to test its validity.
No takes yet. Share an insight, caveat, or question.
Lacasse et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: